Not yet taking people in ItalyPhase 1
Compares how the body handles LY03010 and XEPLION in people with schizophrenia
Tests how the body processes LY03010 compared with XEPLION in adults with schizophrenia.
Key facts
- Who runs it
- Geneora Pharma (Shijiazhuang) Co. Ltd.
- Where
- Bourgas, ItalySee the siteAlso in 3 other countries, 18 sites
- Trial code
- Registry title
- A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 170 people, planned
- Started
- 1 Sept 2024
- Planned end
- 31 Dec 2025
- Type of study
- Interventional
- Record updated
- 27 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with schizophrenia. It compares LY03010 with XEPLION® in how the body absorbs and handles the drug.
- Age
- 18 years or older
- Sex
- Women and men can join.
Where in Italy
Also in 3 other countries, 18 sites
- MENTAL HEALTH CENTER PROF. DR. IVAN TEMKOVBourgas, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Compares how the body handles LY03010 and XEPLION in people with schizophreniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 August 2024